Fig. 4.

Characterization of engineered ¹⁰FN3-based MDM2/X inhibitors MOP3 and MOP3+. (A) Direct and competitive binding assay of MOP3C, MOP3 and MOP3+ to MDM2 as in Fig. 2. (B) Top: T22 reporter activity in transiently transfected cells expressing EGFP-fused MOP constructs compared to EGFP alone or EGFP expressing cells treated with Nutlin, sMTIDE-02 or sMTIDE-02^SCRAM, a scrambled control stapled peptide. Bottom: Representative Western blot image of the expression levels of EGFP-fused MOP constructs (same order as in graph) in T22 and the loading control protein β-actin. Data represent mean ± SD (n = 3).